Survival Plant-Based

NCT ID: NCT06768229

Last Updated: 2025-06-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-09
• Study Completion Date: 2025-05-13

Brief Summary

The aim of this study is to explore the potential of a mix of 4 freeze-dried bifidobacteria strains from Danone collection to survive in human gastro-intestinal (GI) tract of healthy volunteers after 14 days of consumption.

To this aim, one study group of 20 healthy volunteers will consume freeze-dried strains- mix twice per day diluted in 1 glass of still water during 14 consecutive days.

Conditions

A03 - Digestive System; B03 - Bacteria

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Assess the survival of Bifidobacteria's strains in the GI tract after consumption of strains mix

One study group of 20 healthy volunteers will consume freeze-dried strains- mix twice per day diluted in 1 glass of still water during 14 consecutive days.

Group Type: EXPERIMENTAL

Consumption of a freeze-dried strains-mix.

Intervention Type: OTHER

One study group of 20 healthy volunteers will consume freeze-dried strains-mix twice per day diluted in 1 glass of still water during 14 consecutive days.

Interventions

Consumption of a freeze-dried strains-mix.

One study group of 20 healthy volunteers will consume freeze-dried strains-mix twice per day diluted in 1 glass of still water during 14 consecutive days.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Age 18-60 years.

2. Body Mass Index (BMI) between 18.5-30.0 kg/m2.

3. Willing to consume twice per day for at least 14 days the study product diluted in 1 glass of still water.

4. Availability to comply with the protocol and timetable.

5. Having regular bowel movements (on ≥6 days/week).

6. French speaking and reading.

7. Subject willing to adhere to the specific instructions and restrictions for the entire duration of the study.

8. Signed (written) informed consent from participant.

9. Subject is covered by a French health insurance.

10. Agree to be registered in the national database of subjects participating in clinical research.

11. Have a smartphone/computer compatible and connectable to internet, and subject is willing and able to complete the electronic Patient Reported Outcomes (ePRO) using it.

12. Women of childbearing potential must be using a medically approved method of contraception, or be with a surgically sterile partner or be with a partner of the same sex.

Exclusion Criteria

1. Subject who used within 8 weeks prior to the screening visit or are planning to use during the conduct of this study one of the listed prohibited medications that might modify gastrointestinal function. Incidental use (1 or 2 pills/tablets) of non-steroidal anti-inflammatory drugs and aspirin is allowed, if required.

2. Subject following special diet at the screening visit (V1), or plan for such diet during the study.

3. Subject having any previous abdominal surgery, or plan for such surgery during the study.

4. Subject who underwent a general anesthesia in the preceding 4 weeks before the screening visit (V1).

5. Subject with any metabolic disease, hypertension, any inflammatory disease, any psychiatric disorder, or any gastrointestinal disorder, all these medical conditions should have been diagnosed by a physician.

6. Subject with any known food allergy or intolerance to any of the study product components or to any potential traces.

7. Active smoker with 7 or more cigarettes per week.

8. Subject doing high intensity physical activity in combination with following an enhanced diet within 1 month before screening or planned during the participation of the study.

9. Subject who underwent dental surgery within the last 4 weeks before the screening visit (V1) or plan dental surgery during the course of the study.

10. Pregnant woman or woman planning to become pregnant during the study or breastfeeding woman.

11. Participation in another study with investigational or marketed products potentially affecting the gut microbiota ≤ 4 weeks before the screening visit (V1) or plan for participation in any other intervention study during the study.

12. Employees and/or children/family members or relatives of employees of Danone Global Research & Innovation Center or the participating site.

13. Subject under guardianship or curatorship.

14. Excessive alcohol consumption during the past 6 months before the screening visit (V1).

15. Drug abuse, based on investigator's judgment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Danone Global Research & Innovation Center

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

CEN Experimental

Dijon, , France

Countries

France

Other Identifiers

23REX0060157

Identifier Type: -

Identifier Source: org_study_id